AMOXI-CLAV 125 MG — DIN 02326515
CLAVULANIC ACID (POTASSIUM CLAVULANATE) : 125 MG AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 500 MG · PRO DOC LIMITEE · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is AMOXI-CLAV?
AMOXI-CLAV 125 MG contains CLAVULANIC ACID (POTASSIUM CLAVULANATE) : 125 MG AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02326515, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 23-Jan-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is AMOXI-CLAV used for?
Treatment of sinusitis, otitis media, lower respiratory tract infections, skin and soft tissue infections, and urinary tract infections caused by susceptible beta-lactamase producing strains.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Amoxicillin And Beta-Lactamase Inhibitor cost around the world?
Amoxicillin And Beta-Lactamase Inhibitor is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 153 | 166 | SAR███.██ |
| Australia | ex-manufacturer | 34 | 132 | AUD███.██ |
| South Africa | single exit price | 96 | 122 | ZAR███.██ |
| United States | acquisition | 10 | 98 | USD███.██ |
| Bahrain | retail (max) | 36 | 93 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 15 | 41 | CZK███.██ |
| Romania | max producer price | 25 | 41 | RON███.██ |
| Sweden | AIP (pharmacy purchase price) | 14 | 38 | SEK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 18 | 32 | EUR███.██ |
| United Kingdom | hospital | 15 | 15 | GBP███.██ |
| Luxembourg | reimbursement | 9 | 9 | EUR███.██ |
| Iceland | max wholesale | 3 | 5 | ISK███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Hungary | producer price (ex-factory) | 3 | 3 | HUF███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
800 pack listings across 436 brand entries and 14 price bases, refreshed 08 Sep 2026. Ranges span every Amoxicillin And Beta-Lactamase Inhibitor pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Amoxicillin And Beta-Lactamase Inhibitor in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
14 holders have a Canadian DIN containing Amoxicillin And Beta-Lactamase Inhibitor, across 59 DINs, of which 28 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 6 | 5 | JAMP AMOXI CLAV, JAMP AMOXI CLAV SUSPENSION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 5 | 5 | AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION, SANDOZ AMOXI-CLAV TABLET | Sourceable in Canada |
| GLAXOSMITHKLINE INC | 7 | 4 | CLAVULIN 125 F ORAL SUS, CLAVULIN 200, CLAVULIN 250 F ORAL SUS, CLAVULIN 250 TAB, CLAVULIN 400, +2 more | Sourceable in Canada |
| APOTEX INC | 9 | 3 | APO-AMOXI CLAV, APO-AMOXI CLAV 125MG/31.25MG PER 5ML, APO-AMOXI CLAV 250MG/62.5MG PER 5ML, APO-AMOXICILLIN-CLAVULANATE | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-AMOXICLAV | Sourceable in Canada |
| ANGITA PHARMA INC. | 6 | 2 | AG-AMOXI CLAV, AG-AMOXI CLAV SUSPENSION | Sourceable in Canada |
| PRO DOC LIMITEE | 5 | 2 | AMOXI-CLAV, PRO-AMOXI CLAV | Sourceable in Canada |
| MANTRA PHARMA INC | 2 | 2 | M-AMOXI CLAV | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 2 | AMOXICILLIN/CLAV | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 0 | RATIO-ACLAVULANATE, RATIO-ACLAVULANATE 125 F, RATIO-ACLAVULANATE 250 F | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-CLAVAMOXIN 125, NOVO-CLAVAMOXIN 250, NOVO-CLAVAMOXIN 875 | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-AMCLAV-200, PMS-AMCLAV-400, PMS-AMCLAV-875 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 125 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 250/125mg: Bottles of 100 and 500. 500/125mg: Bottles of 100, 250 and 500. 875/125mg: Bottles of 60 and 100. |
| Storage | Store at room temperature (15°C - 30°C). Protect from light and moisture. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Amoxicillin And Beta-Lactamase Inhibitor |
|---|---|
| ATC code | J01CR02 |
| AHFS class | 08:12.16.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02326515 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2326515 |
| Brand name | AMOXI-CLAV |
| Generic / active ingredient | CLAVULANIC ACID (POTASSIUM CLAVULANATE) : 125 MG AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 500 MG |
| Market authorization holder | PRO DOC LIMITEE |
| Health Canada schedule | Prescription |
| ATC code | J01CR02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01CR |
| Current status | CANCELLED POST MARKET |
| Status date | 23-Jan-2018 |
| Original market date | 2009-10-08 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 500 mg q12h; severe infections 875 mg q12h or 500 mg q8h. Children (>=3 months): 20-45 mg/kg/day based on amoxicillin component. Administer at start of meals to minimize GI intolerance.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to penicillins, cephalosporins, or any ingredient; suspected/confirmed infectious mononucleosis; history of amoxicillin/clavulanate-associated jaundice or hepatic dysfunction.
Warnings and precautions
Serious/fatal hypersensitivity (anaphylaxis) possible. Clostridium difficile-associated disease (CDAD) reported. Use caution in hepatic dysfunction. Risk of crystalluria; maintain fluid intake.
Is Amoxicillin And Beta-Lactamase Inhibitor in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
28 of 59 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-AMOXI CLAV | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02510634 |
| AG-AMOXI CLAV | 875 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02510642 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02495910 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 2000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02495937 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 1000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02495929 |
| AMOXICILLIN/CLAV | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | 02536021 |
| AMOXICILLIN/CLAV | 875 MG | TABLET | SANIS HEALTH INC | MARKETED | 02536048 |
| APO-AMOXI CLAV | 125 MG | TABLET | APOTEX INC | MARKETED | 02243350 |
| APO-AMOXI CLAV | 875 MG | TABLET | APOTEX INC | MARKETED | 02245623 |
| APO-AMOXI CLAV | 500 MG | TABLET | APOTEX INC | MARKETED | 02243351 |
2 · Same class — other molecules in ATC J01CR
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Amoxicillin And Beta-Lactamase Inhibitor | AG-AMOXI CLAV · AG-AMOXI CLAV SUSPENSION · AMOXI-CLAV · AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION · +28 more | 59 | 28 | Yes |
| Piperacillin And Beta-Lactamase Inhibitor | JAMP-PIP/TAZ · PIPERACILLIN / TAZOBACTAM POWDER FOR INJECTION · PIPERACILLIN AND TAZOBACTAM FOR INJECTION · PIPERACILLIN/TAZOBACTAM FOR INJECTION · +5 more | 52 | 16 | Yes |
| Ticarcillin And Beta-Lactamase Inhibitor | TIMENTIN | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01CA | Amoxicillin · Ampicillin · Ampicillin, Combinations · Bacampicillin · Piperacillin · +3 more | 201 | 47 |
| J01CF | Beta-Lactamase Resistant Penicillins · Cloxacillin · Flucloxacillin | 42 | 9 |
| J01CE | Benzathine Benzylpenicillin · Benzathine Phenoxymethylpenicillin · Benzylpenicillin · Combinations · Phenoxymethylpenicillin · +1 more | 69 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AMOXI-CLAV called?
The same molecule, Amoxicillin And Beta-Lactamase Inhibitor, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| AUGMENTIN | Latin | Bahrain, Czechia |
| Amoxil | Latin | Australia, Bahrain |
| APO-Amoxycillin | Latin | Australia |
| Amoxycillin Sandoz | Latin | Australia |
| Omacillin | Latin | Bahrain, Saudi Arabia |
| Amimox® | Latin | Sweden |
| Betaklav | Latin | Czechia, Sweden |
| KLAVOX | Latin | Bahrain |
| AMILOXYN | Latin | Australia |
| APX-Amoxicillin/Clavulanic Acid | Latin | Australia |
| Cilamox | Latin | Australia |
| COMOX | Latin | Australia |
| Curam | Latin | Australia, Bahrain |
| AMOXICILLIN-WGR | Latin | Australia |
| MOXICLAV | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.